Hepatic Impairment Articles & Analysis
9 news found
Cebranopadol is being studied with once daily dosing and has shown no need for dose adjustment in patients with renal or hepatic impairment or with food. About Tris Pharma Tris Pharma is a privately held, fully integrated and innovation-driven CNS company that provides a differentiated approach to target unmet medical needs, including the application of novel ...
Pitolisant is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in women breastfeeding their children. ...
Reduction in dosage of IGALMI or the concomitant medication should be considered. USE IN SPECIFIC POPULATIONS Hepatic Impairment and Geriatric Patients (≥65 years old): A lower dose is recommended in patients with hepatic impairment and geriatric patients. ...
Orviglance is Ascelia Pharma’s oral investigational MRI imaging agent used in the visualization of cancer in the liver and is currently in Phase 3 development. The Hepatic Impairment Study evaluates if patients with different degrees of hepatic impairment can tolerate Orviglance since Orviglance is selectively taken up and ...
Thyroid Dysfunction: Monitor before initiation and throughout treatment with FOTIVDA. Risk of Impaired Wound Healing: Withhold FOTIVDA for at least 24 days before elective surgery. ...
Risk of Driving and Operating Machinery: Dizziness, somnolence, and mental status changes have occurred in patients taking KORSUVA. KORSUVA may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. ...
Thyroid Dysfunction: Monitor before initiation and throughout treatment with FOTIVDA. Risk of Impaired Wound Healing: Withhold FOTIVDA for at least 24 days before elective surgery. ...
Fatalities due to adverse reactions occurred in 4.3% of patients including interstitial lung disease (2.6%), and the following events occurred in one patient each (0.4%): acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemorrhagic shock. ...
BAVENCIO Safety Profile from the EU Summary of Product Characteristics (SmPC) The special warnings and precautions for use for BAVENCIO include infusion-related reactions and immune-related adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction, and other adverse reactions). ...